Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity

Antiviral Research

Volumn 89, Issue 2, 2011, Pages 136-148

  Gentzsch, Juliane ^a   Hinkelmann, Bettina ^b   Kaderali, Lars ^c   Irschik, Herbert ^b   Jansen, Rolf ^b   Sasse, Florenz ^b   Frank, Ronald ^b   Pietschmann, Thomas ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiviral therapy; Chronic liver disease; HCV; Hepatitis C virus; Tartrolon; Viral life cycle

Indexed keywords

LUCIFERASE; SMALL MOLECULE TRANSPORT AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME RELEASE; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIFE CYCLE; MYXOCOCCALES; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPORTER GENE; VALIDATION PROCESS; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS RELEASE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; GROWTH SUBSTANCES; HEPACIVIRUS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; VIRUS REPLICATION;

HEPATITIS C VIRUS; MYXOCOCCALES;

EID: 78751634447     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.12.005     Document Type: Article

References (97)

1. Atzori F., Fornier M. Epothilones in breast cancer: current status and future directions. Expert Rev. Anticancer Ther. 2008, 8:1299-1311.
2. Balzarini J., Pannecouque C., De Clercq E., Pavlov A.Y., Printsevskaya S.S., Miroshnikova O.V., Reznikova M.I., Preobrazhenskaya M.N. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J. Med. Chem. 2003, 46:2755-2764.
3. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197:633-642.
4. Bartosch B., Verney G., Dreux M., Donot P., Morice Y., Penin F., Pawlotsky J.M., Lavillette D., Cosset F.L. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 2005, 79:8217-8229.
5. Birk A.V., Dubovi E.J., Zhang X., Szeto H.H. Antiviral activity of geneticin against bovine viral diarrhoea virus. Antivir. Chem. Chemother. 2008, 19:33-40.
6. Bitzegeio J., Bankwitz D., Hueging K., Haid S., Brohm C., Zeisel M.B., Herrmann E., Iken M., Ott M., Baumert T.F., Pietschmann T. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog. 2010, 6:e1000978.
7. Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., Rouille Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80:6964-6972.
8. Blight K.J., McKeating J.A., Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 2002, 76:13001-13014.
9. Boulant S., Douglas M.W., Moody L., Budkowska A., Targett-Adams P., McLauchlan J. Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic 2008, 9:1268-1282.
10. Bourne N., Pyles R.B., Yi M., Veselenak R.L., Davis M.M., Lemon S.M. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res. 2005, 67:76-82.
11. Brown R.S. Hepatitis C and liver transplantation. Nature 2005, 436:973-978.
12. Cannon P.M., Kim N., Kingsman S.M., Kingsman A.J. Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J. Virol. 1996, 70:8234-8240.
13. Casey J.R., Grinstein S., Orlowski J. Sensors and regulators of intracellular pH. Nat. Rev. Mol. Cell Biol. 2010, 11:50-61.
14. Chang K.S., Jiang J., Cai Z., Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 2007, 81:13783-13793.
15. Chockalingam K., Simeon R.L., Rice C.M., Chen Z. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3764-3769.
16. Ciesek S., Steinmann E., Iken M., Ott M., Helfritz F.A., Wappler I., Manns M.P., Wedemeyer H., Pietschmann T. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010, 138:1875-1884.
17. Deterding K., Wiegand J., Grüner N., Wedemeyer H. Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care?. J. Hepatol. 2008, 48:1019-1020.
18. DuBridge R.B., Tang P., Hsia H.C., Leong P.M., Miller J.H., Calos M.P. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell Biol. 1987, 7:379-387.
19. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72:8463-8471.
20. Elnakady Y.A., Sasse F., Lünsdorf H., Reichenbach H. Disorazol A1, a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells. Biochem. Pharmacol. 2004, 67:927-935.
21. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
22. Friebe P., Boudet J., Simorre J.P., Bartenschlager R. Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J. Virol. 2005, 79:380-392.
23. Gastaminza P., Cheng G., Wieland S., Zhong J., Liao W., Chisari F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008, 82:2120-2129.
24. Gastaminza P., Kapadia S.B., Chisari F.V. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J. Virol. 2006, 80:11074-11081.
25. Gastaminza P., Whitten-Bauer C., Chisari F.V. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:291-296.
26. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., Moradpour D. Identification of the hepatitis C virus RNA replication complex in huh-7 cells harboring subgenomic replicons. J. Virol. 2003, 77:5487-5492.
27. Gottwein J.M., Scheel T.K., Jensen T.B., Lademann J.B., Prentoe J.C., Knudsen M.L., Hoegh A.M., Bukh J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49:364-377.
28. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10583-10587.
29. Griffin S.D., Beales L.P., Clarke D.S., Worsfold O., Evans S.D., Jaeger J., Harris M.P., Rowlands D.J. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. 2003, 535:34-38.
30. Haid S., Windisch M.P., Bartenschlager R., Pietschmann T. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J. Virol. 2010, 84:964-975.
31. Hijikata M., Mizushima H., Akagi T., Mori S., Kakiuchi N., Kato N., Tanaka T., Kimura K., Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 1993, 67:4665-4675.
32. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
33. Hopkins C.D., Wipf P. Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides. Nat. Prod. Rep. 2009, 26:585-601.
34. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., McKeating J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7271-7276.
35. Huang H., Sun F., Owen D.M., Li W., Chen Y., Gale M., Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5848-5853.
36. Huss M., Sasse F., Kunze B., Jansen R., Steinmetz H., Ingenhorst G., Zeeck A., Wieczorek H. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem. 2005, 6:13.
37. Irschik H., Schummer D., Gerth K., Höfle G., Reichenbach H. The tartrolons, new boron-containing antibiotics from a myxobacterium, Sorangium cellulosum. J. Antibiot. (Tokyo) 1995, 48:26-30.
38. Irschik H., Schummer D., Höfle G., Reichenbach H., Steinmetz H., Jansen R. Etnangien, a macrolide-polyene antibiotic from Sorangium cellulosum that inhibits nucleic acid polymerases. J. Nat. Prod. 2007, 70:1060-1063.
39. Jones C.T., Murray C.L., Eastman D.K., Tassello J., Rice C.M. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol. 2007, 81:8374-8383.
40. Kalajzic I., Stover M.L., Liu P., Kalajzic Z., Rowe D.W., Lichtler A.C. Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology 2001, 284:37-45.
41. Kapadia S.B., Chisari F.V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2561-2566.
42. Kaptein S.J., De Burghgraeve T., Froeyen M., Pastorino B., Alen M.M., Mondotte J.A., Herdewijn P., Jacobs M., de Lamballerie X., Schols D., Gamarnik A.V., Sztaricskai F., Neyts J. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob. Agents Chemother. 2010, 54:5269-5280.
43. Kohno J., Kawahata T., Otake T., Morimoto M., Mori H., Ueba N., Nishio M., Kinumaki A., Komatsubara S., Kawashima K. Boromycin, an anti-HIV antibiotic. Biosci. Biotechnol. Biochem. 1996, 60:1036-1037.
44. Koutsoudakis G., Kaul A., Steinmann E., Kallis S., Lohmann V., Pietschmann T., Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 2006, 80:5308-5320.
45. Lai C.K., Jeng K.S., Machida K., Lai M.M. Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A. J. Virol. 2008, 82:8838-8848.
46. Lemon S.M., Walker C.M., Alter M.J., Yi M. Hepatitis C Virus. Fields Virology 2007, 1253-1304. Lipincott Williams & Wilkins, Philadelphia. 5 edn. D.M. Knipe, P.M. Howley (Eds.).
47. Li Q., Brass A.L., Ng A., Hu Z., Xavier R.J., Liang T.J., Elledge S.J. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16410-16415.
48. Lindenbach B.D., Evans M.J., Syder A.J., Wölk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
49. Liu S., Yang W., Shen L., Turner J.R., Coyne C.B., Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009, 83:2011-2014.
50. Lohmann V., Körner F., Koch J.O., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
51. Maheshwari A., Ray S., Thuluvath P.J. Acute hepatitis C. Lancet 2008, 372:321-332.
52. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
53. Martinez-Bauer E., Forns X., Armelles M., Planas R., Solà R., Vergara M., Fabregàs S., Vega R., Salmerón J., Diago M., Sánchez-Tapias J.M., Bruguera M. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J. Hepatol. 2008, 48:20-27.
54. Meertens L., Bertaux C., Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 2006, 80:11571-11578.
55. Meunier J.C., Engle R.E., Faulk K., Zhao M., Bartosch B., Alter H., Emerson S.U., Cosset F.L., Purcell R.H., Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4560-4565.
56. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., Bartenschlager R., Wakita T., Hijikata M., Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 2007, 9:1089-1097.
57. Mondal R., Koev G., Pilot-Matias T., He Y., Ng T., Kati W., Molla A. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well. Antiviral Res. 2009, 82:82-88.
58. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5:453-463.
59. Mulzer J., Berger M. Total synthesis of the boron-containing ion carrier antibiotic macrodiolide tartrolon B. J. Org. Chem. 2004, 69:891-898.
60. Nahmias Y., Goldwasser J., Casali M., van Poll D., Wakita T., Chung R.T., Yarmush M.L. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 2008, 47:1437-1445.
61. Ng T.I., Mo H., Pilot-Matias T., He Y., Koev G., Krishnan P., Mondal R., Pithawalla R., He W., Dekhtyar T., Packer J., Schurdak M., Molla A. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007, 45:1413-1421.
62. Nickeleit I., Zender S., Sasse F., Geffers R., Brandes G., Sörensen I., Steinmetz H., Kubicka S., Carlomagno T., Menche D., Gütgemann I., Buer J., Gossler A., Manns M.P., Kalesse M., Frank R., Malek N.P. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008, 14:23-35.
63. Pavlović D., Neville D.C., Argaud O., Blumberg B., Dwek R.A., Fischer W.B., Zitzmann N. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6104-6108.
64. Peng L.F., Kim S.S., Matchacheep S., Lei X., Su S., Lin W., Runguphan W., Choe W.H., Sakamoto N., Ikeda M., Kato N., Beeler A.B., Porco J.A., Schreiber S.L., Chung R.T. Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen. Antimicrob. Agents Chemother. 2007, 51:3756-3759.
65. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., Abid K., Negro F., Dreux M., Cosset F.L., Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7408-7413.
66. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
67. Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P., Rice C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-886.
68. Popescu C.I., Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol. Cell 2010, 102:63-74.
69. Premkumar A., Wilson L., Ewart G.D., Gage P.W. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett. 2004, 557:99-103.
70. Reichenbach H., Höfle G. Myxobacteria as producers of secondary metabolites. Drug discovery from Nature 1999, 149-179. Springer Verlag. S. Grabley, R. Thieriecke (Eds.).
71. Reichenbach H., Höfle G. Discovery and development of the epothilones: a novel class of antineoplastic drugs. Drugs R.D. 2008, 9:1-10.
72. Rieber N., Knapp B., Eils R., Kaderali L. RNAither, an automated pipeline for the statistical analysis of high-throughput RNAi screens. Bioinformatics 2009, 25:678-679.
73. Roohvand F., Maillard P., Lavergne J.P., Boulant S., Walic M., Andreo U., Goueslain L., Helle F., Mallet A., McLauchlan J., Budkowska A. Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. J. Biol. Chem. 2009, 284:13778-13791.
74. Sasse F., Steinmetz H., Heil J., Hofle G., Reichenbach H. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J. Antibiot. (Tokyo) 2000, 53:879-885.
75. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
76. Schinazi R.F., Bassit L., Gavegnano C. HCV drug discovery aimed at viral eradication. J. Viral Hepat. 2010, 17:77-90.
77. Schummer D., Schomburg D., Irschik H., Reichenbach H., Höfle G. Antibiotics from gliding bacteria, LXXV: Absolute configuration and biosynthesis of tartrolon B, a boron-containing macrodiolide from Sorangium cellulosum. Liebigs Ann. 1996, 965-969.
78. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.
79. Simmonds P., Bukh J., Combet C., Deléage G., Enomoto N., Feinstone S., Halfon P., Inchauspé G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
80. Steinmann E., Brohm C., Kallis S., Bartenschlager R., Pietschmann T. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J. Virol. 2008, 82:7034-7046.
81. Steinmann E., Penin F., Kallis S., Patel A.H., Bartenschlager R., Pietschmann T. Hepatitis C virus p7 protein Is crucial for assembly and release of infectious virions. PloS Pathog. 2007, 3:e103.
82. Steinmann E., Whitfield T., Kallis S., Dwek R.A., Zitzmann N., Pietschmann T., Bartenschlager R. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007, 46:330-338.
83. Tai A.W., Benita Y., Peng L.F., Kim S.S., Sakamoto N., Xavier R.J., Chung R.T. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009, 5:298-307.
84. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 2006, 80:1734-1741.
85. Voisset C., Callens N., Blanchard E., Op De Beeck A., Dubuisson J., Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 2005, 280:7793-7799.
86. von Hahn T., Lindenbach B.D., Boullier A., Quehenberger O., Paulson M., Rice C.M., McKeating J.A. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 2006, 43:932-942.
87. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
88. Wang C., Gale M., Keller B.C., Huang H., Brown M.S., Goldstein J.L., Ye J. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol. Cell 2005, 18:425-434.
89. Watashi K. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr. Opin. Investig. Drugs 2010, 11:213-224.
90. Wenzel S.C., Müller R. Myxobacteria - 'microbial factories' for the production of bioactive secondary metabolites. Mol. Biosyst. 2009, 5:567-574.
91. Westby M., van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 2005, 16:339-354.
92. Westby M., van der Ryst E. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir. Chem. Chemother. 2010, 20:179-192.
93. Wölk B., Büchele B., Moradpour D., Rice C.M. A dynamic view of hepatitis C virus replication complexes. J. Virol. 2008, 82:10519-10531.
94. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 2007, 3:e108.
95. Ye J., Wang C., Sumpter R., Brown M.S., Goldstein J.L., Gale M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15865-15870.
96. Zhang X.G., Mason P.W., Dubovi E.J., Xu X., Bourne N., Renshaw R.W., Block T.M., Birk A.V. Antiviral activity of geneticin against dengue virus. Antiviral Res. 2009, 83:21-27.
97. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9294-9299.